Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by McGuire Investment Group LLC


Share on StockTwits

McGuire Investment Group LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 50,550 shares of the company’s stock after buying an additional 4,148 shares during the quarter. Medpace makes up about 1.7% of McGuire Investment Group LLC’s holdings, making the stock its 24th biggest holding. McGuire Investment Group LLC’s holdings in Medpace were worth $7,037,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of MEDP. Scout Investments Inc. lifted its stake in shares of Medpace by 3.8% in the 4th quarter. Scout Investments Inc. now owns 103,688 shares of the company’s stock valued at $14,433,000 after purchasing an additional 3,800 shares during the last quarter. State of Michigan Retirement System purchased a new position in shares of Medpace during the 3rd quarter worth approximately $1,106,000. Equitable Trust Co. acquired a new stake in Medpace in the 3rd quarter valued at approximately $239,000. Voloridge Investment Management LLC purchased a new stake in Medpace in the third quarter valued at approximately $4,997,000. Finally, Sei Investments Co. lifted its stake in Medpace by 40.3% during the third quarter. Sei Investments Co. now owns 55,329 shares of the company’s stock worth $6,188,000 after purchasing an additional 15,896 shares in the last quarter. Institutional investors own 70.81% of the company’s stock.

Shares of MEDP traded up $0.29 during midday trading on Wednesday, hitting $140.44. The company had a trading volume of 169,053 shares, compared to its average volume of 234,232. Medpace Holdings, Inc. has a 1 year low of $58.72 and a 1 year high of $150.57. The firm has a market capitalization of $5.02 billion, a P/E ratio of 42.86 and a beta of 1.34. The company’s 50-day simple moving average is $137.09 and its 200-day simple moving average is $121.00.

Medpace (NASDAQ:MEDP) last issued its earnings results on Saturday, October 31st. The company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.02. Medpace had a net margin of 13.87% and a return on equity of 17.67%. The firm had revenue of $230.37 million for the quarter, compared to analysts’ expectations of $223.56 million. During the same quarter last year, the company earned $0.71 earnings per share. The firm’s revenue was up 6.5% compared to the same quarter last year. On average, analysts anticipate that Medpace Holdings, Inc. will post 4 EPS for the current year.

MEDP has been the topic of several research analyst reports. BidaskClub upgraded Medpace from a “buy” rating to a “strong-buy” rating in a report on Friday, December 11th. Zacks Investment Research upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $159.00 price target on the stock in a research note on Tuesday. Finally, Truist raised shares of Medpace from a “hold” rating to a “buy” rating and increased their price target for the stock from $124.00 to $135.00 in a research report on Friday, October 2nd. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $110.00.

In other news, CEO August J. Troendle sold 216,048 shares of the company’s stock in a transaction dated Friday, December 18th. The stock was sold at an average price of $141.85, for a total transaction of $30,646,408.80. Following the completion of the transaction, the chief executive officer now directly owns 666,643 shares of the company’s stock, valued at approximately $94,563,309.55. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 1,374 shares of the stock in a transaction dated Monday, December 28th. The shares were sold at an average price of $140.00, for a total value of $192,360.00. Following the completion of the transaction, the chief executive officer now owns 706,643 shares in the company, valued at approximately $98,930,020. The disclosure for this sale can be found here. Insiders sold a total of 532,750 shares of company stock worth $74,888,848 over the last 90 days. Company insiders own 26.00% of the company’s stock.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

See Also: Is a Roth IRA right for you?

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.